COVID-19 Vaccines: Regulatory Consortium Addresses Way Forward With Immunobridging Studies
Executive Summary
Drug regulators from five countries have outlined their joint expectations on the data companies must submit for the approval of next-generation COVID-19 vaccines if they opt for immunobridging studies instead of large-scale efficacy trials.